Declan Doogan

Director · Tenax Therapeutics

Declan Doogan (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Tenax Therapeutics, Inc. (TENX). Across 1 priced purchase filing, the average 21-session return was -18.4% from execution and -20.1% from disclosure (delay-adjusted; derived). The largest single filing was $102K of TENX (53,000 sh × $1.92, as filed), executed Sep 16. Data as of Nov 8 2026.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

-18.4%

avg across 1 priced filings

Delay-adjustediThe same average, entered at disclosure dates

-20.1%

same 1 filings, from disclosure

Filings, ttm

1 buys · 0 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$102K

shares × price, as filed

Last traded

Sep 16

Filed Sep 17

Median ADV $7.2M across their filed names

Open performance→

Volume by month

Buys $102K Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 1 filing

Sector per market data · by filing · past 12 months

Most traded names

TENX

Tenax Therapeutics, Inc. TENX · 1 buy · 0 sells 1 filing

Recent filings

TENXPURCHASE Tenax Therapeutics, Inc. View filing → $102K
53,000 sh × $1.92
Exec Sep 16
Filed Sep 17 · 9:30 PM ET